640 related articles for article (PubMed ID: 16670102)
1. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome.
Blank SK; McCartney CR; Marshall JC
Hum Reprod Update; 2006; 12(4):351-61. PubMed ID: 16670102
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty.
Blank SK; McCartney CR; Helm KD; Marshall JC
Semin Reprod Med; 2007 Sep; 25(5):352-9. PubMed ID: 17710731
[TBL] [Abstract][Full Text] [Related]
3. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
McCartney CR; Eagleson CA; Marshall JC
Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
[TBL] [Abstract][Full Text] [Related]
4. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
5. The gonadotropic axis in hyperandrogenic adolescents.
Taylor AE
J Pediatr Endocrinol Metab; 2000; 13 Suppl 5():1281-4. PubMed ID: 11117670
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine dysfunction in polycystic ovary syndrome.
Burt Solorzano CM; Beller JP; Abshire MY; Collins JS; McCartney CR; Marshall JC
Steroids; 2012 Mar; 77(4):332-7. PubMed ID: 22172593
[TBL] [Abstract][Full Text] [Related]
7. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
Hayes FJ; Taylor AE; Martin KA; Hall JE
J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
[TBL] [Abstract][Full Text] [Related]
8. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients.
Moret M; Stettler R; Rodieux F; Gaillard RC; Waeber G; Wirthner D; Giusti V; Tappy L; Pralong FP
Neuroendocrinology; 2009; 89(2):131-9. PubMed ID: 18832802
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine control in polycystic ovary-like syndrome.
Schoemaker J
Gynecol Endocrinol; 1991 Dec; 5(4):277-88. PubMed ID: 1796749
[TBL] [Abstract][Full Text] [Related]
10. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria.
Lewandowski KC; Cajdler-Luba A; Bieńkiewicz M; Lewiński A
Neuro Endocrinol Lett; 2011; 32(6):847-56. PubMed ID: 22286802
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine aspects of polycystic ovary syndrome.
Marshall JC; Eagleson CA
Endocrinol Metab Clin North Am; 1999 Jun; 28(2):295-324. PubMed ID: 10352920
[TBL] [Abstract][Full Text] [Related]
12. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Pastor CL; Griffin-Korf ML; Aloi JA; Evans WS; Marshall JC
J Clin Endocrinol Metab; 1998 Feb; 83(2):582-90. PubMed ID: 9467578
[TBL] [Abstract][Full Text] [Related]
13. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
[TBL] [Abstract][Full Text] [Related]
14. The role of changing pulse frequency in the regulation of ovulation.
Marshall JC; Griffin ML
Hum Reprod; 1993 Nov; 8 Suppl 2():57-61. PubMed ID: 8276970
[TBL] [Abstract][Full Text] [Related]
15. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
16. Interrelationship between excessive levels of circulating androgens in blood and ovulatory failure.
Parker CR; Mahesh VB
J Reprod Med; 1976 Aug; 17(2):75-90. PubMed ID: 134158
[TBL] [Abstract][Full Text] [Related]
17. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
[TBL] [Abstract][Full Text] [Related]
18. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
Cheung AP; Lu JK; Chang RJ
Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls.
Panidis D; Farmakiotis D; Koliakos G; Rousso D; Kourtis A; Katsikis I; Asteriadis C; Karayannis V; Diamanti-Kandarakis E
Hum Reprod; 2005 Aug; 20(8):2127-32. PubMed ID: 15890737
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
